8-K Announcements
6Material company update
Apr 27, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 12, 2026·SEC
Fulcrum Therapeutics, Inc.(FULC)Earnings, Financials & Key Ratios
FULC•NASDAQ
$3.72
Price updated Jul 6, 2026
AboutFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$83M-310.7%
- Net Income-$75M-670.0%
- EPS (Diluted)-1.18-637.5%
- ROE-25.3%-522.0%
FULC Price & Volume
Fulcrum Therapeutics, Inc. (FULC) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Recurring Revenue Streams
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical Trial Binary Risk
Key Thesis Takeaways
- Fulcrum Therapeutics remains a high-risk, pre-revenue biotechnology entity heavily reliant on the success of its FulcrumSeek platform and the Phase 3 REACH trial.
- While the firm maintains a temporary liquidity buffer, the persistent quarterly R&D burn rate of approximately $14.5 million and the lack of recurring commercial revenue suggest significant long-term dilution risk.
- Investors should remain cautious as the company's valuation is currently tethered to binary clinical outcomes rather than sustainable operational profitability.
Verdict Logic
the company's reliance on external capital to fund operations is underscored by a cash position that declined from $197.5 million in 2025Q4 to $50.3 million by 2026Q1.
FULC Growth Metrics
Fulcrum Therapeutics, Inc. (FULC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14824.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1542.86%
Return on Capital
10 Years-209.46%
5 Years-37.9%
3 Years-28.58%
Last Year-28.12%
FULC Recent Earnings
Fulcrum Therapeutics, Inc. (FULC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (75%)
Q2 2026Latest
Apr 27, 2026Metric
Actual
Est
EPS
$0.25+19.4%
$0.31
Rev
—
—
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.31+0.0%
$0.31
Rev
—
—
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.31-6.9%
$0.29
Rev
—
—
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.28+3.4%
$0.29
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 27, 2026 | $0.25vs $0.31+19.4% | — |
| Q1 2026 | Feb 24, 2026 | $0.31vs $0.31+0.0% | — |
| Q4 2025 | Oct 29, 2025 | $0.31vs $0.29-6.9% | — |
| Q3 2025 | Jul 29, 2025 | $0.28vs $0.29+3.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Fulcrum Therapeutics, Inc. (FULC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.72 | $201.29M | -3.15 | -100% | — | -25.3% | — | |
| $86.55 | $12.19B | -7094.26 | 23258.15% | -48.38% | -55.09% | — | |
| $19.18 | $2.02B | -2.69 | 15.58% | 2.98% | 4.89% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $61.89 | $5.97B | -9.57 | -89.97% | -13856.54% | -30.88% | — |
Compare FULC vs Peers
Fulcrum Therapeutics, Inc. (FULC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FULC SEC Filings & Documents
Fulcrum Therapeutics, Inc. (FULC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when FULC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FULC Frequently Asked Questions
Fulcrum Therapeutics, Inc. (FULC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Fulcrum Therapeutics, Inc. growing?
Fulcrum Therapeutics, Inc. (FULC) saw revenue decline by 100.0% over the past year.
Is FULC profitable?
Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $76.1M for fiscal year 2025.
Dividend & Returns
What is FULC's return on equity?
Fulcrum Therapeutics, Inc. (FULC) has a return on equity (ROE) of -25.3%. Negative ROE indicates the company is unprofitable.
What is Fulcrum Therapeutics, Inc.'s free cash flow?
Fulcrum Therapeutics, Inc. (FULC) had negative free cash flow of $63.9M in fiscal year 2025, likely due to heavy capital investments.